Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole for GERD in Infants
NCT00468559Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of esomeprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Number of Participants Discontinuing Due to Symptom Worsening in the Randomized Treatment Withdrawal Phase at 4 weeks. Started Apr 2007; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00468559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00468559.